Meeting
2013 ASCO Annual Meeting
Safety and tolerability of adjuvant dose dense chemotherapy in elderly patients with node-positive early breast cancer.
Authors
Vasilios Karavasilis
Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
Vasilios Karavasilis , Dimitrios G. Pectasides , Christos A. Papadimitriou , Helen Gogas , George Kouvatseas , Christos Christodoulou , Angelos Koutras , George E. Pentheroudakis , Helena Linardou , Evangelia Razis , Gerasimos Aravantinos , Meletios A. Dimopoulos , George Fountzilas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1093)
DOI
10.1200/jco.2013.31.15_suppl.1093
Abstract #
1093
Poster Bd #
26A
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
The adjuvant PANTHER study: A randomized comparison between dose-dense and tailored epirubicin (E), cyclophosphamide (C) and docetaxel (D) vs. standard dose 5-fluorouracil (F), epirubicin (E), cyclophosphamide (C) and docetaxel—Health-related quality of life during ongoing therapy.
First Author: Yvonne Brandberg
Poster
2011 ASCO Annual Meeting
Benefit from CMF with or without anthracyclines in relation to biologic profiles in early breast cancer.
First Author: A. Rocca
First Author: Begoña Bermejo
Poster
2013 ASCO Annual Meeting
Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2).
First Author: Volker Moebus